| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
45,450,000 |
| Market
Cap: |
28.33(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6234 - $0.6234 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Co.'s phospholipid drug conjugate (PDC) therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. Co.'s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets. The CLR 1900 Series is being developed for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Longcor Jarrod |
Chief Operating Officer |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
42,927 |
53,141 |
|
- |
|
| Shustov Andrei |
Senior Vice President, Medical |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
47,856 |
55,038 |
|
- |
|
| Caruso James V |
President and CEO |
• • – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
40,596 |
49,236 |
|
- |
|
| Lea Darrell Shane |
Chief Commercial Officer |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
39,599 |
39,599 |
|
- |
|
| Kolean Chad J |
Chief Financial Officer |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
42,554 |
42,578 |
|
- |
|
| Shustov Andrei |
Senior Vice President, Medical |
• – – |
2023-02-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,181 |
|
- |
|
| Swirsky Douglas J |
Director |
– • – |
2021-09-14 |
4 |
B |
$1.04 |
$26,000 |
D/D |
25,000 |
25,000 |
2.39 |
-47% |
|
| Driscoll Frederick W |
Director |
– • – |
2021-09-03 |
4 |
B |
$1.04 |
$20,244 |
D/D |
19,417 |
19,417 |
2.39 |
-32% |
|
| Caruso James V |
President and CEO |
• • – |
2021-03-04 |
4 |
B |
$1.70 |
$8,659 |
D/D |
5,100 |
86,401 |
2.81 |
-37% |
|
| Elefant Dov |
Chief Financial Officer |
• – – |
2020-12-28 |
4 |
B |
$1.35 |
$9,999 |
D/D |
7,407 |
11,755 |
2.74 |
-34% |
|
| Caruso James V |
President and CEO |
• • – |
2020-12-28 |
4 |
B |
$1.35 |
$50,000 |
D/D |
37,037 |
81,301 |
2.81 |
-34% |
|
| Longcor Jarrod |
Chief Business Officer |
• – – |
2020-12-28 |
4 |
B |
$1.35 |
$40,001 |
D/D |
29,630 |
102,148 |
2.74 |
-34% |
|
| Longcor Jarrod |
Chief Business Officer |
• – – |
2020-06-05 |
4 |
B |
$1.15 |
$74,675 |
D/D |
65,218 |
72,518 |
2.74 |
8% |
|
| Caruso James V |
President and CEO |
• • – |
2020-06-05 |
4 |
B |
$1.15 |
$24,892 |
D/D |
21,740 |
44,264 |
2.81 |
8% |
|
| Elefant Dov |
Chief Financial Officer |
• – – |
2020-06-05 |
4 |
B |
$1.15 |
$4,978 |
D/D |
4,348 |
4,348 |
2.66 |
8% |
|
| Hill Stephen A |
Director |
– • – |
2020-06-04 |
4 |
B |
$1.08 |
$19,438 |
D/D |
18,000 |
18,000 |
2.39 |
8% |
|
| Elefant Dov |
Chief Financial Officer |
• – – |
2020-02-03 |
4 |
A |
$2.71 |
$27,100 |
D/D |
10,000 |
10,000 |
|
- |
|
| Longcor Jarrod |
Chief Business Officer |
• – – |
2020-02-03 |
4 |
A |
$2.71 |
$108,400 |
D/D |
40,000 |
40,000 |
|
- |
|
| Caruso James V |
President and CEO |
• • – |
2020-02-03 |
4 |
A |
$2.71 |
$271,000 |
D/D |
100,000 |
100,000 |
|
- |
|
| Longcor Jarrod |
Chief Business Officer |
• – – |
2019-02-28 |
4 |
B |
$2.00 |
$200 |
D/D |
100 |
7,300 |
2.66 |
- |
|
| Caruso James V |
President and CEO |
• • – |
2018-11-30 |
4 |
B |
$2.28 |
$2,282 |
D/D |
1,000 |
22,354 |
2.73 |
- |
|
| Hill Stephen A |
Director |
– • – |
2018-11-29 |
4 |
S |
$2.21 |
$2,192 |
D/D |
(992) |
0 |
|
- |
|
| Longcor Jarrod |
Chief Business Officer |
• – – |
2018-08-16 |
4 |
B |
$2.71 |
$1,355 |
D/D |
500 |
7,200 |
2.66 |
- |
|
| Longcor Jarrod |
Chief Business Officer |
• – – |
2018-03-13 |
4 |
AS |
$1.18 |
$15,397 |
D/D |
(13,000) |
67,000 |
|
- |
|
| Caruso James V |
President and CEO |
• • – |
2018-03-12 |
4 |
AS |
$1.20 |
$40,705 |
D/D |
(34,000) |
213,548 |
|
- |
|
90 Records found
|
|
Page 1 of 4 |
|
|
